British biotech developing RNA-based therapeutics and delivery technologies for oncology and cardiovascular disease.
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Funding round Thalia Therapeutics raised funding from new and existing investors to support its transition into a clinical-stage RNA therapeutics business. | $3.6M |
Tap an investor to see what else they have backed.
Thalia Therapeutics has acquired Sanmirna Therapeutics.
Data is community-curated and may be incomplete.